<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899962</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-1004</org_study_id>
    <nct_id>NCT02899962</nct_id>
  </id_info>
  <brief_title>LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris</brief_title>
  <official_title>LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol&#xD;
      foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis&#xD;
      vulgaris.&#xD;
&#xD;
      A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm,&#xD;
      parallel group trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After an initial 4-week period of once-daily treatment with open-label active LEO 90100&#xD;
      aerosol foam, subjects who qualify for randomisation will continue into a 52-week maintenance&#xD;
      treatment period with twice-weekly application of randomised LEO 90100 aerosol foam / LEO&#xD;
      90100 aerosol foam vehicle.&#xD;
&#xD;
      If the subject experiences a relapse of psoriasis, the active lesions will be treated for 4&#xD;
      weeks with open-label active LEO 90100 aerosol foam.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Relapse</measure>
    <time_frame>From Randomisation (Week 4) until first relapse or End of Treatment (Week 56 or early withdrawal)</time_frame>
    <description>Time to first relapse (at least 'mild' according to the Physician's Global Assessment of disease severity [PGA]). The investigator was to grade the severity of psoriasis of the trunk and limbs using Physician's global assessment of disease severity 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days in Remission During the Maintenance Phase</measure>
    <time_frame>From Randomisation (Week 4) until End of Treatment (Week 56 or early withdrawal)</time_frame>
    <description>Remission defined as 'clear' or 'almost clear' according to the PGA. The investigator was to grade using a global assessment of the disease severity of psoriasis of the trunk and limbs using the PGA 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses During the Maintenance Phase</measure>
    <time_frame>From Randomisation (Week 4) until End of Treatment (Week 56)</time_frame>
    <description>Defined as number of 4-week periods with use of once-daily rescue investigational medicinal product</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">722</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical application twice weekly for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 90100 aerosol foam vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical application twice weekly for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 aerosol foam</intervention_name>
    <description>LEO 90100 aerosol foam twice weekly</description>
    <arm_group_label>LEO 90100 aerosol foam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 aerosol foam vehicle</intervention_name>
    <description>LEO 90100 aerosol foam vehicle twice weekly</description>
    <arm_group_label>LEO 90100 aerosol foam vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  A clinical diagnosis of psoriasis vulgaris for at least 6 months involving the trunk&#xD;
             and/or limbs, amenable to treatment with maximum of 100 g of trial medication per week&#xD;
&#xD;
          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and&#xD;
             skin folds) involving 2-30% of the body surface area (BSA)&#xD;
&#xD;
          -  A target lesion/target location of at least 3 cm at its longest axis located on the&#xD;
             body (i.e., not on the scalp, face or intertriginous areas), scoring at least 1&#xD;
             ('mild') for each of redness, thickness and scaliness, and at least 4 in total by the&#xD;
             Investigator's Assessment of Severity of the Target Lesion/Location&#xD;
&#xD;
        For subjects participating in hypothalamic-pituitary-adrenal (HPA)-axis testing,&#xD;
        furthermore:&#xD;
&#xD;
          -  An extent of psoriasis vulgaris on trunk and/or limbs of disease severity (PGA) of at&#xD;
             least 'moderate' affecting between 10 and 30% of the body surface area (BSA) excluding&#xD;
             psoriatic lesions of genitals and skin folds at Visit 1.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Systemic treatment with biological therapies, whether marketed or not, with a possible&#xD;
             effect on psoriasis vulgaris within the following time periods prior to Visit 1:&#xD;
&#xD;
               -  etanercept - within 4 weeks prior to Visit 1&#xD;
&#xD;
               -  adalimumab, infliximab - within 8 weeks prior to Visit 1&#xD;
&#xD;
               -  ustekinumab - within 16 weeks prior to Visit 1&#xD;
&#xD;
               -  secukinumab - within 12 weeks prior to Visit 1&#xD;
&#xD;
               -  other products - within 4 weeks/5 half-lives prior to Visit 1 (whichever is&#xD;
                  longer)&#xD;
&#xD;
          -  Systemic treatment with all other therapies with a possible effect on psoriasis&#xD;
             vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other&#xD;
             immunosuppressants) within 4 weeks prior to Visit 1&#xD;
&#xD;
          -  Systemic treatment with apremilast within 4 weeks prior to Visit 1&#xD;
&#xD;
          -  Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to Visit 1&#xD;
&#xD;
          -  Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1&#xD;
&#xD;
          -  Severe and/or extensive scalp psoriasis which, in the opinion of the investigator,&#xD;
             requires treatment with potent or super-potent corticosteroids which will be&#xD;
             prohibited during the trial&#xD;
&#xD;
        For subjects participating in HPA-axis testing, furthermore:&#xD;
&#xD;
          -  Antidepressive medications within 4 weeks prior to Visit 1 or during the trial.&#xD;
             Oestrogen therapy (including contraceptives), antidepressant medications and any other&#xD;
             medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior&#xD;
             to baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Lebwohl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermAssociates</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center - New Center One</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central NJ</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Department of Dermatology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivergate Dermatology Clinical Research Center</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Dermaesthetics</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 4M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maritime Medical Research Centre</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <zip>E2A 4Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brunwick Dermatology Center</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCA Medical Research</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research Incorporated</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Guenther Dermatology Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Center for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Dre Isabelle Delorme Inc</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Saint-Etienne Service de Dermatologie</name>
      <address>
        <city>Saint Etienne</city>
        <state>Saint-Etienne</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de nice, Hôpital de l'Archet II, Service de Dermatologie-Vénérologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valence</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR), Klinik für Dermatologie</name>
      <address>
        <city>Essen</city>
        <zip>54122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH - Campus Lübeck</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Sebastian</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Poliklinik Derma &amp; Allergo</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemein. Weber &amp; Crainic</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Małopolskie Centrum Kliniczne</name>
      <address>
        <city>Kraków</city>
        <zip>31-123</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Med-laser</name>
      <address>
        <city>Lublin</city>
        <zip>20-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solumed</name>
      <address>
        <city>Poznań</city>
        <zip>60-425</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewódzki, Klinika Dermatologii</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wansford and Kings Cliffe Prac</name>
      <address>
        <city>Wansford</city>
        <state>Cambridgeshire</state>
        <zip>PE8 6PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashgate Medical Practice</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burbage Surgery</name>
      <address>
        <city>Burbage</city>
        <state>Leicstershire</state>
        <zip>LE10 2SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany House Medical Centre</name>
      <address>
        <city>Wellingborough</city>
        <state>Northamptonshire</state>
        <zip>NN8 4RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherbourne Medical Centre</name>
      <address>
        <city>Leamington Spa</city>
        <state>Warwickshire</state>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatopharmacology Department</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <results_first_submitted>July 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02899962/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02899962/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>722 subjects were screened of which 650 subjects were assigned to treatment with LEO 90100 open-label phase. Subjects did not progress from screening due to adverse event=1, lost to follow-up=2, other reasons=2, screening failures=52, and withdrawal by subject=15. All 650 subjects were exposed to LEO 90100 during the open-label phase</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open-label LEO 90100</title>
          <description>In the open-label phase, LEO 90100, an aerosol foam formulation containing calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) was applied once daily on the body for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Maintenance LEO 90100</title>
          <description>In the maintenance phase, subjects from open-label phase who achieved treatment success according to Physician's Global Assessment of disease severity (clear or almost clear with 2-step improvement) were randomised to receive LEO 90100 twice weekly for 52 weeks. In case of relapse (psoriasis which was mild, moderate or severe according to PGA), rescue medication was applied. Rescue medication was LEO 90100 applied once daily on the body for 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Maintenance Vehicle</title>
          <description>In the maintenance phase, subjects from open-label phase who achieved treatment success according to Physician's Global Assessment of disease severity (clear or almost clear with 2-step improvement) were randomised to receive vehicle twice weekly for 52 weeks. In case of relapse (psoriasis which was mild, moderate or severe according to PGA), rescue medication was applied. Rescue medication was LEO 90100 applied once daily on the body for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="650"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="623"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="272"/>
                <participants group_id="P3" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not achieve treatment success after Wk 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not clear/almost clear after rescue med</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Included all subjects exposed to LEO 90100 at the start of open-label phase</population>
      <group_list>
        <group group_id="B1">
          <title>LEO 90100 Open-label Phase</title>
          <description>LEO 90100, an aerosol foam formulation containing calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) was applied once daily on the body for 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="650"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Data available only from 635 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="635"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="584"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PGA</title>
          <description>The investigator was to grade the severity of psoriasis of the trunk and limbs using the 5-point scale Physician's global assessment of the disease severity:&#xD;
Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Relapse</title>
        <description>Time to first relapse (at least 'mild' according to the Physician's Global Assessment of disease severity [PGA]). The investigator was to grade the severity of psoriasis of the trunk and limbs using Physician's global assessment of disease severity 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
        <time_frame>From Randomisation (Week 4) until first relapse or End of Treatment (Week 56 or early withdrawal)</time_frame>
        <population>Full analysis set: included all subjects randomised who had treatment success at randomisation, defined as PGA score of 'clear' or 'almost clear' with at least a 2-grade improvement from baseline</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Aerosol Foam</title>
            <description>Topical application of LEO 90100 aerosol foam twice weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Aerosol Foam Vehicle</title>
            <description>Topical application of LEO 90100 aerosol foam vehicle twice weekly for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Relapse</title>
          <description>Time to first relapse (at least 'mild' according to the Physician's Global Assessment of disease severity [PGA]). The investigator was to grade the severity of psoriasis of the trunk and limbs using Physician's global assessment of disease severity 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
          <population>Full analysis set: included all subjects randomised who had treatment success at randomisation, defined as PGA score of 'clear' or 'almost clear' with at least a 2-grade improvement from baseline</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="34" upper_limit="59"/>
                    <measurement group_id="O2" value="30" lower_limit="29" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All randomized subjects were considered for statistical analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The primary endpoint was time to first relapse during the maintenance phase. This was calculated as the number of days from randomisation to the day where the subject had the first relapse confirmed. For subjects who either did not encounter a relapse or were withdrawn from the trial, the number of days was treated as a censored observation at the day of end of trial visit.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
            <estimate_desc>Estimates are obtained from a proportional hazards model with treatment group,pooled trial site,disease severity at maintenance baseline (Week 4; determined by PGA) as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days in Remission During the Maintenance Phase</title>
        <description>Remission defined as 'clear' or 'almost clear' according to the PGA. The investigator was to grade using a global assessment of the disease severity of psoriasis of the trunk and limbs using the PGA 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
        <time_frame>From Randomisation (Week 4) until End of Treatment (Week 56 or early withdrawal)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Aerosol Foam</title>
            <description>Topical application of LEO 90100 aerosol foam twice weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Aerosol Foam Vehicle</title>
            <description>Topical application of LEO 90100 aerosol foam vehicle twice weekly for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days in Remission During the Maintenance Phase</title>
          <description>Remission defined as 'clear' or 'almost clear' according to the PGA. The investigator was to grade using a global assessment of the disease severity of psoriasis of the trunk and limbs using the PGA 5-point scale: Clear = 0; Almost clear = 1; Mild = 2; Moderate = 3; Severe = 4</description>
          <units>Proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" spread="21.7"/>
                    <measurement group_id="O2" value="60.8" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The number of days in remission was calculated as the sum of days where the subject was in remission periods. The proportion of days in remission was calculated as the number of days in remission divided by the length of the maintenance phase in days.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Factors adjusted for in the ANOVA model were treatment group, pooled trial site, and disease severity at maintenance baseline (PGA).</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
            <estimate_desc>Multiple imputation of data for withdrawn subjects was done using 100 imputations and depended on whether the subject's reason for withdrawal potentially was related to treatment. Length of the maintenance phase was assumed to be 52 weeks (364 days)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses During the Maintenance Phase</title>
        <description>Defined as number of 4-week periods with use of once-daily rescue investigational medicinal product</description>
        <time_frame>From Randomisation (Week 4) until End of Treatment (Week 56)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100 Aerosol Foam</title>
            <description>Topical application of LEO 90100 aerosol foam twice weekly for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>LEO 90100 Aerosol Foam Vehicle</title>
            <description>Topical application of LEO 90100 aerosol foam vehicle twice weekly for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapses During the Maintenance Phase</title>
          <description>Defined as number of 4-week periods with use of once-daily rescue investigational medicinal product</description>
          <units>relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.7"/>
                    <measurement group_id="O2" value="3.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Poisson regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>The number of relapses was analysed using a Poisson regression model with treatment group,pooled sites,disease severity at maintenance baseline as factors, subject as random effect, and time at risk as an offset.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks during the open-label phase and 52 weeks during the maintenance phase and 8 weeks during the safety follow-up</time_frame>
      <desc>All adverse events were reported by the subjects or observed by the investigators were recorded</desc>
      <group_list>
        <group group_id="E1">
          <title>LEO 90100 Aerosol Foam Open-label</title>
          <description>Topical application once daily for 4 weeks&#xD;
LEO 90100 aerosol foam open-label</description>
        </group>
        <group group_id="E2">
          <title>LEO 90100 Aerosol Foam</title>
          <description>Topical application twice weekly for 52 weeks&#xD;
LEO 90100 aerosol foam: LEO 90100 aerosol foam twice weekly</description>
        </group>
        <group group_id="E3">
          <title>LEO 90100 Aerosol Foam Vehicle</title>
          <description>Topical application twice weekly for 52 weeks&#xD;
LEO 90100 aerosol foam vehicle: LEO 90100 aerosol foam vehicle twice weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="650"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="650"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="650"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E3" events="24" subjects_affected="15" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="650"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="272"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="650"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rebound psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="650"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="650"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="650"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO Pharma acknowledges the investigators' right to publish the entire results of the study, irrespective of outcome. LEO Pharma retains the right to have any publication submitted to LEO Pharma for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO Pharma.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Specialist</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

